Evolving insight of adverse drug reaction associated with breast cancer drugs

Abstract

Cancer begins when genes mutate and cause cell proliferation in an uncontrollable manner. Breast cancer develops in females in the lobules and ducts of breast cells. As per the American Institute of Cancer Research, Breast cancer is diagnosed as the second leading cause of death in women if not noticed at the early stages of treatment. In recent decades, the widespread awareness and improvements in the screening and treatment of breast cancer have lowered the mortality rate of breast cancer by 40%. However, drugs for breast cancer therapy do carry adverse effects. Worldwide efforts are ongoing to detect and to neutralize these adverse effects. That is why it is inevitable to bring it to the notice of physicians through adverse drug reaction monitoring of anticancer drugs. This paper explores some of the variables causing these ADRs in the individual case reports that has been assembled via different renowned journal databases such as Google Scholar, Science Direct, Cochrane Library & PubMed. Accustomized breast cancer medications such as5-fluorouracil, cisplatin, sunitinib, doxorubicin, cyclophosphamide, & topotecanare being used in the treatment of breast cancer. A specific approach to monitor the ADR is necessary to deal with them. This review addresses the complexity of the ADRs that can subsequently be used by the clinicians who are serving in the tertiary health care system.